Cullinan Therapeutics (CGEM) Assets Average (2021 - 2026)

Cullinan Therapeutics' Assets Average history runs 6 years deep, the most recent figure standing at $425.7 million for Q1 2026.

• On a quarterly basis, Assets Average fell 29.14% year-over-year to $425.7 million in Q1 2026; TTM through Mar 2026 was $425.7 million, a 29.14% decrease from a year earlier, with the FY2025 full-year figure at $535.1 million, down 3.24% from the prior year.
• Assets Average eased to $425.7 million in Q1 2026 per CGEM's latest filing, from $466.2 million in the prior quarter.
• Across five years, Assets Average topped out at $667.2 million in Q3 2024 and bottomed at $425.7 million in Q1 2026.
• The 5-year median for Assets Average is $538.1 million (2023), against an average of $538.7 million.
• Across the five-year window, Assets Average jumped 39.96% in 2022 and retreated 29.14% in 2026, its largest moves.
• Year by year, Assets Average stood at $589.2 million in 2022, then dropped by 16.93% to $489.4 million in 2023, then surged by 30.26% to $637.5 million in 2024, then slipped by 26.87% to $466.2 million in 2025, then declined by 8.7% to $425.7 million in 2026.
• Per Business Quant, the three latest CGEM Assets Average figures stand at $425.7 million (Q1 2026), $466.2 million (Q4 2025), and $502.2 million (Q3 2025).